MoonLake Immunotherapeutics
MLTX· Nasdaq
Released Aug 7, 2024, before the open
10-Q filed Aug 7, 2024, 38 days after period end · 0001821586-24-000025
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$24.27M | -$10.14M | -$12.12M | -$32.69M |
| EPS Diluted | -$0.39 | -$0.23 | -$0.34 | -$2.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MoonLake Immunotherapeutics · CIK 1821586 · Engraved from SEC EDGAR